Laura M. Heiser - Publications

Affiliations: 
Lawrence Berkeley National Laboratory, Berkeley, CA, USA 
Area:
spatial cognition

61 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Kimmel GJ, Dane M, Heiser LM, Altrock PM, Andor N. Integrating mathematical modeling with high throughput imaging explains how polyploid populations behave in nutrient-sparse environments. Cancer Research. PMID 32938640 DOI: 10.1158/0008-5472.CAN-20-1231  0.311
2020 Smith R, Devlin K, Liu M, Liby T, Kilburn D, Bucher E, Sudar D, Thibault G, Dane M, Gray J, Heiser L, Korkola JE. Abstract 1870: The impact of the microenvironment on heterogeneity and trametinib response in HCC1143 triple negative breast cancer cells Cancer Research. 80: 1870-1870. DOI: 10.1158/1538-7445.Am2020-1870  0.34
2019 Meyer AS, Heiser LM. Systems biology approaches to measure and model phenotypic heterogeneity in cancer. Current Opinion in Systems Biology. 17: 35-40. PMID 32864511 DOI: 10.1016/j.coisb.2019.09.002  0.32
2019 Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, Simon LM, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, Shaw C, ... ... Heiser LM, et al. . Molecular Cancer Research : McR. PMID 31420371 DOI: 10.1158/1541-7786.Mcr-19-0756  0.356
2019 Smith R, Devlin K, Kilburn D, Gross S, Sudar D, Bucher E, Nederlof M, Dane M, Gray JW, Heiser L, Korkola JE. Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer. Journal of Visualized Experiments : Jove. PMID 31180341 DOI: 10.3791/58957  0.307
2019 Coleman DJ, Gao L, King CJ, Schwartzman J, Urrutia J, Sehrawat A, Tayou J, Balter A, Burchard J, Chiotti KE, Derrick DS, Sun D, Xia Z, Heiser LM, Alumkal JJ. BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer. Oncogene. PMID 30996246 DOI: 10.1038/s41388-019-0815-5  0.311
2019 Heiser LM, Mills GB, Gray JW. Therapeutic Clues from an Integrated Omic Assessment of East Asian Triple Negative Breast Cancers. Cancer Cell. 35: 341-343. PMID 30889376 DOI: 10.1016/j.ccell.2019.02.012  0.321
2019 Coleman DJ, Gao L, Schwartzman J, Korkola JE, Sampson D, Derrick DS, Urrutia J, Balter A, Burchard J, King CJ, Chiotti KE, Heiser LM, Alumkal JJ. Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer. Scientific Reports. 9: 3823. PMID 30846826 DOI: 10.1038/s41598-019-40518-5  0.335
2019 Keck JM, Parmar S, Kong B, Mitri Z, Corless C, Kolodzie A, Creason A, Goecks J, Leyshock P, Siex K, Johnson BE, Patterson J, Heiser L, Olson A, Viehdorfer M, et al. Abstract 4929: Leveraging multi-omics tumor boards for precision medicine in the OHSU SMMART Treatments Program Cancer Research. 79: 4929-4929. DOI: 10.1158/1538-7445.Sabcs18-4929  0.34
2018 Sehrawat A, Gao L, Wang Y, Bankhead A, McWeeney SK, King CJ, Schwartzman J, Urrutia J, Bisson WH, Coleman DJ, Joshi SK, Kim DH, Sampson DA, Weinmann S, Kallakury BVS, ... ... Heiser LM, et al. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proceedings of the National Academy of Sciences of the United States of America. PMID 29581250 DOI: 10.1073/Pnas.1719168115  0.308
2018 Watson SS, Dane M, Chin K, Tatarova Z, Liu M, Liby T, Thompson W, Smith R, Nederlof M, Bucher E, Kilburn D, Whitman M, Sudar D, Mills GB, Heiser LM, et al. Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Systems. PMID 29550255 DOI: 10.1016/j.cels.2018.02.001  0.359
2018 Johnson B, Keck J, Morris M, Siex K, Kolodzie A, Parmar S, Riesterer J, Chin K, Gibbs S, Heiser L, Spellman P, Ellrott K, Babur O, Demir E, Margolin A, et al. Abstract 3296: SMMART: Serial measurements of molecular and architectural responses to therapy Cancer Research. 78: 3296-3296. DOI: 10.1158/1538-7445.Am2018-3296  0.35
2017 King CJ, Woodward J, Schwartzman J, Coleman DJ, Lisac R, Wang NJ, Van Hook K, Gao L, Urrutia J, Dane MA, Heiser LM, Alumkal JJ. Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer. Oncotarget. 8: 111084-111095. PMID 29340039 DOI: 10.18632/oncotarget.22560  0.346
2017 Hafner M, Heiser LM, Williams EH, Niepel M, Wang NJ, Korkola JE, Gray JW, Sorger PK. Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics. Scientific Data. 4: 170166. PMID 29112189 DOI: 10.1038/sdata.2017.166  0.323
2017 Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, ... ... Heiser LM, et al. Combating subclonal evolution of resistant cancer phenotypes. Nature Communications. 8: 1231. PMID 29093439 DOI: 10.1038/S41467-017-01174-3  0.362
2017 Korkola JE, Collisson EA, Heiser LM, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, et al. Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. Plos One. 12: e0186551. PMID 29020035 DOI: 10.1371/Journal.Pone.0186551  0.314
2017 Hassan S, Esch A, Liby T, Gray JW, Heiser LM. Pathway-enriched gene signature associated with 53BP1 response to PARP inhibition in triple-negative breast cancer. Molecular Cancer Therapeutics. PMID 28958991 DOI: 10.1158/1535-7163.Mct-17-0170  0.341
2017 Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang NJ, Ng CKY, Chen E, Renwick A, Wang T, Nanda S, et al. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28487443 DOI: 10.1158/1078-0432.Ccr-16-2191  0.357
2017 Rahman M, MacNeil SM, Jenkins DF, Shrestha G, Wyatt SR, McQuerry JA, Piccolo SR, Heiser LM, Gray JW, Johnson WE, Bild AH. Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes. Genome Medicine. 9: 40. PMID 28446242 DOI: 10.1186/s13073-017-0429-x  0.301
2017 Hassan S, Esch A, Heiser LM, Gray JW. Abstract B24: Genomic prediction of response to PARP inhibition in breast cancer Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-B24  0.36
2017 Korkola J, Liu M, Smith R, Liby T, Heiser L, Gray J. Abstract P6-08-01: A directed siRNA screen identifies INHBA as a major regulator of tumor aggressiveness in basal HER2 breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-08-01  0.37
2016 Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, et al. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 113: E6600-E6609. PMID 27791031 DOI: 10.1073/Pnas.1612835113  0.336
2016 Hu Z, Mao JH, Curtis C, Huang G, Gu S, Heiser L, Lenburg ME, Korkola JE, Bayani N, Samarajiwa S, Seoane JA, A Dane M, Esch A, Feiler HS, Wang NJ, et al. Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Research : Bcr. 18: 70. PMID 27368372 DOI: 10.1186/S13058-016-0728-Y  0.314
2016 Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave M, Korkola JE, Gao L, ... Heiser LM, et al. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget. PMID 27276681 DOI: 10.18632/oncotarget.9816  0.309
2016 Gao L, Coleman DJ, King CJ, Schwartzman J, Wang N, Esch A, Urrutia J, Sehrawat A, Heiser LM, Alumkal JJ. Abstract 4700: BET bromodomain inhibition is a promising treatment strategy for distinct subsets of lethal castration-resistant prostate cancer Cancer Research. 76: 4700-4700. DOI: 10.1158/1538-7445.Am2016-4700  0.328
2015 Esch A, Heiser L, Gray JW. Biological indicators of response and resistance to PARP inhibition in BRCA wild-type breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 125. PMID 28147797 DOI: 10.1200/Jco.2015.33.28_Suppl.125  0.332
2015 Lue HW, Cole B, Rao SA, Podalak J, Van Gaest A, King C, Eide CA, Wilmot B, Xue C, Spellman PT, Heiser LM, Tyner JW, Thomas GV. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma. Oncotarget. PMID 26625308 DOI: 10.18632/Oncotarget.5971  0.312
2015 Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-derived Cell Lines as Molecular Models of Cancer Pharmacogenomics. Molecular Cancer Research : McR. PMID 26248648 DOI: 10.1158/1541-7786.Mcr-15-0189  0.331
2015 Korkola JE, Collisson EA, Heiser L, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, et al. Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. Plos One. 10: e0133219. PMID 26181325 DOI: 10.1371/Journal.Pone.0133219  0.35
2015 Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, Contreras A, Gutierrez C, Wang T, Hilsenbeck SG, De Angelis C, Wang NJ, Heiser LM, Gray JW, et al. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26015514 DOI: 10.1158/1078-0432.CCR-14-2728  0.302
2015 Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, et al. Erratum to: Modeling precision treatment of breast cancer. Genome Biology. 16: 95. PMID 25962591 DOI: 10.1186/S13059-015-0658-5  0.306
2015 Korkola JE, Liu M, Liby T, Heiser L, Feiler H, Gray JW. Abstract S6-07: Detrimental effects of sequential compared to concurrent treatment of pertuzumab plus T-DM1 in HER2+ breast cancer cell lines Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S6-07  0.304
2015 Fu X, Jeselsohn R, Hollingsworth EF, Lopez-Terrada D, Creighton CJ, Nardone A, Shea M, Heiser LM, Anur P, Wang N, Grasso C, Spellman P, Gutierrez C, Rimawi MF, Hilsenbeck SG, et al. Abstract PD6-2: FoxA1 gene amplification in ER+ breast cancer mediates endocrine resistance by increasing IL-8 Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd6-2  0.319
2015 Xu X, Nardone A, Hu H, Qin L, Nanda S, Heiser LM, Wang N, Covington KR, Chen ES, Renwick A, Wang T, Angelis CD, Contreras A, Gutierrez C, Fuqua SA, et al. Abstract P5-05-03: Clonal evolution of the HER2 L755S mutation leads to acquired HER-targeted therapy resistance that can be reversed by the irreversible HER1/2 inhibitor afatinib Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-05-03  0.329
2015 Wolf DM, Yau C, Sanil A, Daemen A, Heiser L, Gray J, Brown-Swigart L, Flynn S, Hirst G, Investigators IT, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, et al. Abstract P3-06-05: Evaluation of anin vitroderived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL: Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-05  0.314
2015 Qin L, Hahn MB, Fu X, Shea MJ, Giuliano M, Nanda S, Xu X, Hu H, Jung SY, Heiser LM, Wang N, Gray JW, Hilsenbeck SG, Creighton C, Shaw CA, et al. Abstract P3-05-13: Overexpression of insulin receptor substrate 4 can mediate acquired resistance to lapatinib-containing regimens in HER2+ breast cancer cells Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-05-13  0.355
2015 Woodward J, King C, Coleman D, Lisac R, Schwartzman J, Wang N, Gleave M, Gray J, Thomas G, Beer TM, Hook KV, Baertsch R, Goldstein T, Stuart J, Gao L, ... ... Heiser L, et al. Abstract 731: Integrative genomic analysis to identify emergent enzalutamide resistance mechanisms in castration-resistant prostate cancer Cancer Research. 75: 731-731. DOI: 10.1158/1538-7445.Am2015-731  0.345
2015 Hu H, Simon L, Qin L, Nardone A, Shaw C, Chamness G, Heiser L, Wang N, Gray JW, Osborne CK, Schiff R. Abstract 721: Mevalonate pathway mediates acquired anti-HER2 treatment resistance in HER2+ breast cancer Cancer Research. 75: 721-721. DOI: 10.1158/1538-7445.Am2015-721  0.356
2015 Coleman D, Hook KV, Lisac R, King C, Wang N, Schwartzman J, Gleave M, Gao L, Urrutia J, Heiser L, Alumkal JJ. Abstract 3592: Androgens interfere with enzalutamide agonism of mutant F876L androgen receptor Cancer Research. 75: 3592-3592. DOI: 10.1158/1538-7445.Am2015-3592  0.314
2014 Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, ... Heiser LM, et al. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Research : Bcr. 16: 430. PMID 25212826 DOI: 10.1186/S13058-014-0430-X  0.33
2014 Alumkal JJ, Heiser L, Beer TM, Small EJ, Baertsch R, Stuart J, King C, Korkola J, Cetnar J, Graff JN, Thomas G, Ryan CW, Toschi A, Youngren J, Tucker E, et al. Identifying enzalutamide resistance mechanisms in men with castration-resistant prostate cancer. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps5104  0.319
2014 Risom T, Rantala J, Langer E, Wang N, Heiser L, Troxell M, Gray J, Sears R. Abstract LB-222: Differentiation state heterogeneity in breast cancer and its role in therapeutic response Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-222  0.361
2014 Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK. Abstract 5502: Metrics other than potency reveal systematic variation in responses to cancer drugs Cancer Research. 74: 5502-5502. DOI: 10.1158/1538-7445.Am2014-5502  0.31
2013 Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, et al. Modeling precision treatment of breast cancer. Genome Biology. 14: R110. PMID 24176112 DOI: 10.1186/Gb-2013-14-10-R110  0.334
2013 Heiser LM, Shaw CA, Wang NJ, Grasso C, Anur P, Ng S, Goldstein T, Spellman PT, Stuart J, Osborne K, Gray J, Schiff R. Abstract 5238: Acquired therapeutic resistance is mediated by deregulation of multiple pathways. Cancer Research. 73: 5238-5238. DOI: 10.1158/1538-7445.Am2013-5238  0.362
2013 Korkola JE, Rantala J, Bayani N, Heiser L, Wang N, Griffith O, Gray J. Abstract 2387: Activation of Inhibin A signaling is associated with a basal-like HER2 subtype and resistance to lapatinib in breast cancer cell lines. Cancer Research. 73: 2387-2387. DOI: 10.1158/1538-7445.Am2013-2387  0.386
2012 Ordinario E, Han HJ, Furuta S, Heiser LM, Jakkula LR, Rodier F, Spellman PT, Campisi J, Gray JW, Bissell MJ, Kohwi Y, Kohwi-Shigematsu T. ATM suppresses SATB1-induced malignant progression in breast epithelial cells. Plos One. 7: e51786. PMID 23251624 DOI: 10.1371/Journal.Pone.0051786  0.32
2012 Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 109: 2724-9. PMID 22003129 DOI: 10.1073/Pnas.1018854108  0.353
2011 Listerman I, Gazzaniga FS, Heiser LM, Lukas JJ, Goldstein T, Haussler D, Gray JW, Blackburn EH. Abstract A58: Wnt signaling pathway components are associated with telomerase activity in breast cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-A58  0.366
2011 Korkola J, Bayani N, Cooper B, Heiser LM, Spellman PT, Feiler HS, Wooster R, Gray JW. Abstract 639: Inhibition of HER2 signaling using targeted therapeutics in breast cancer cell lines Cancer Research. 71: 639-639. DOI: 10.1158/1538-7445.Am2011-639  0.38
2011 Ng S, Vaske C, Benz S, Durbin J, Szeto C, Heiser L, Wang N, Korkola J, Bayani N, Spellman P, Gray JW, Haussler D, Stuart J. Abstract 49: Constructing pathway based predictors of cancer clinical outcome Cancer Research. 71: 49-49. DOI: 10.1158/1538-7445.Am2011-49  0.343
2010 Gibb WJ, Collisson E, Korkola J, Heiser L, Sadanandam A, Kuo W, Hu Z, Mao J, Wang N, Bayani N, Billig J, Ziyad S, Lewis S, Feiler H, Jakkula L, et al. Abstract 1979: Algebraic factorization of gene expression profiles reveals subtype-specific drug sensitivities among 54 breast cancer cell lines Cancer Research. 70: 1979-1979. DOI: 10.1158/1538-7445.Am10-1979  0.333
2009 Kuo WL, Das D, Ziyad S, Bhattacharya S, Gibb WJ, Heiser LM, Sadanandam A, Fontenay GV, Hu Z, Wang NJ, Bayani N, Feiler HS, Neve RM, Wyrobek AJ, Spellman PT, et al. A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. Bmc Medicine. 7: 77. PMID 20003408 DOI: 10.1186/1741-7015-7-77  0.33
2009 Heiser LM, Wang NJ, Talcott CL, Laderoute KR, Knapp M, Guan Y, Hu Z, Ziyad S, Weber BL, Laquerre S, Jackson JR, Wooster RF, Kuo WL, Gray JW, Spellman PT. Integrated analysis of breast cancer cell lines reveals unique signaling pathways. Genome Biology. 10: R31. PMID 19317917 DOI: 10.1186/Gb-2009-10-3-R31  0.352
2009 Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Research. 69: 565-72. PMID 19147570 DOI: 10.1158/0008-5472.Can-08-3389  0.341
2007 Berman RA, Heiser LM, Dunn CA, Saunders RC, Colby CL. Dynamic circuitry for updating spatial representations. III. From neurons to behavior. Journal of Neurophysiology. 98: 105-21. PMID 17493922 DOI: 10.1152/Jn.00330.2007  0.726
2006 Heiser LM, Colby CL. Spatial updating in area LIP is independent of saccade direction. Journal of Neurophysiology. 95: 2751-67. PMID 16291805 DOI: 10.1152/jn.00054.2005  0.649
2005 Colby CL, Berman RA, Heiser LM, Saunders RC. Corollary discharge and spatial updating: when the brain is split, is space still unified? Progress in Brain Research. 149: 187-205. PMID 16226585 DOI: 10.1016/S0079-6123(05)49014-7  0.722
2005 Berman RA, Heiser LM, Saunders RC, Colby CL. Dynamic circuitry for updating spatial representations. I. Behavioral evidence for interhemispheric transfer in the split-brain macaque. Journal of Neurophysiology. 94: 3228-48. PMID 15888534 DOI: 10.1152/jn.00028.2005  0.724
2005 Heiser LM, Berman RA, Saunders RC, Colby CL. Dynamic circuitry for updating spatial representations. II. Physiological evidence for interhemispheric transfer in area LIP of the split-brain macaque. Journal of Neurophysiology. 94: 3249-58. PMID 15888533 DOI: 10.1152/jn.00029.2005  0.728
2004 Berman RA, Heiser LM, Saunders RC, Colby CL. Visuospatial updating in the split-brain Journal of Vision. 4: 887-887. DOI: 10.1167/4.8.887  0.68
Show low-probability matches.